The 2004 WHO classification of endocrine tumors defines pheochromocytoma as a tumor arising from catecholamine-producing chromaffin cells in the adrenal medulla -- an intra-adrenal paraganglioma.
The obligatory adrenal insufficiency caused by surgery must be adequately substituted with hydrocortisone; additional fludrocortisone might also be necessary with high doses of mitotane.
In view of the array of symptoms, the patient was referred for medical evaluation of a suspected pheochromocytoma, a neuroendocrine tumor of the adrenal gland. He underwent 24-hour blood pressure ...
Treatment for pheochromocytoma involves blood pressure medications followed by surgery, usually laparoscopic (minimally invasive) removal of one or both adrenal glands. Cushing’s syndrome is a ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
This summary explores recent research comparing laparoscopic and robotic techniques for adrenalectomy, highlighting their effectiveness, safety, and overall outcomes. Recent studies have focused ...
A pheochromocytoma is a paraganglioma that arises in adrenal gland tissue, which results in the overproduction of adrenal hormones (epinephrine and norepinephrine). People with familial paranganglioma ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The Department of Urology in AIIMS Bhopal successfully treated 13 hormonally active adrenal tumors in the past year using advanced laparoscopic techniques, demonstrating the institution's innovation ...
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback